<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867412</url>
  </required_header>
  <id_info>
    <org_study_id>PERALUST</org_study_id>
    <nct_id>NCT00867412</nct_id>
  </id_info>
  <brief_title>Randomized Study of Positron Emission Tomography - Computed Tomography (PET/CT) in Pre-Operative Staging of Lung Cancer</brief_title>
  <official_title>Randomized Study of PET/CT in Pre-Operative Staging of Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Centre for Health Technology Assessment</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with possible operable non-small cell lung cancer are randomised to conventional&#xD;
      staging, or conventional staging and PET/CT. According to, patients with operable tumor will&#xD;
      be referred to surgery, and the number of thoracotomies and futile thoracotomies wil be&#xD;
      compared with the two groups in order to asses the possible benefit of PET/CT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with possible operable NSCLC after staging with CT are randomised to PET-CT with FDG&#xD;
      or not, prior to mediastinoscopy. All patients are referred to mediastinoscopy unless a&#xD;
      positive FDG uptake results in a positive biopsy suggesting stage IV disease.&#xD;
&#xD;
      Biopsies are performed according to the following criteria:&#xD;
&#xD;
        1. Lymph nodes are numbered according the Mountain classification, and abnormal lesions&#xD;
           must be confirmed histologically, by mediastinoscopy or thoracotomy.&#xD;
&#xD;
        2. PET-positive lesions in the liver must be biopsied unless ultrasound or MRI&#xD;
           unequivocally indicate the lesions are benign cysts or haemangioma.&#xD;
&#xD;
        3. PET-negative adrenal lesions are accepted without biopsy if CT scan indicate the lesion&#xD;
           is a benign adenoma.&#xD;
&#xD;
        4. PET-positive bone lesions must be evaluated by plain x-ray, CT, MRI, or bone&#xD;
           scintigraphy. In case of equivocal findings a biopsy must be performed.&#xD;
&#xD;
        5. PET-positive brain lesions must be confirmed by CT or MRI.&#xD;
&#xD;
      Number of patients:&#xD;
&#xD;
      Patients with clinically operable NSCLC after CT-staging are included. All patients must have&#xD;
      mediastinoscopy performed.&#xD;
&#xD;
      All patients referred to mediastinoscopy can be randomised after informed consent. A total of&#xD;
      430 consecutive, non-selected patients are planned. It is anticipated that approximately 60%&#xD;
      of the referred patients with clinical stage I-IIIa NSCLC will undergo thoracotomy, and a&#xD;
      risk of type I and II error of 5% and 10%, respectively, is accepted. Thus a total of 215&#xD;
      patients are randomised in each arm in order to observe an absolute difference of 15% in the&#xD;
      number of thoracotomies. This number seems to be sufficient to evaluate differences in the&#xD;
      secondary endpoints.&#xD;
&#xD;
      After inclusion of a total of 220 patients, corresponding to 110 PET-scans, an interim&#xD;
      analyses are performed. In case of a highly significant difference in the number of&#xD;
      thoracotomies (p &lt; 0,001) the study will be closed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of futile thoracotomies</measure>
    <time_frame>Within 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of thoracotomies and survival</measure>
    <time_frame>Within 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">189</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Thoracotomy</condition>
  <arm_group>
    <arm_group_label>Conventional staging</arm_group_label>
    <description>Staging with CT, mediastinoscopy and bronchoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional staging and PET/CT</arm_group_label>
    <description>Staging with CT, mediastinoscopy and bronchoscopy, and PET/CT performed prior to mediastinoscopy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-small cell lung cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinically operable NSCLC after CT&#xD;
&#xD;
          2. Fit for thoracotomy and lobectomy or pneumectomy after lung function tests&#xD;
&#xD;
          3. CT-scan of thorax, including liver and adrenals with no signs of distant metastases.&#xD;
&#xD;
          4. No medical condition contraindication surgery.&#xD;
&#xD;
          5. Age 18-80&#xD;
&#xD;
          6. No claustrophobia.&#xD;
&#xD;
          7. Negative pregnancy test.&#xD;
&#xD;
          8. No diabetes mellitus.&#xD;
&#xD;
          9. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Radiologically M1 disease.&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Known claustrophobia.&#xD;
&#xD;
          4. Estimated FEV1 &lt; 30% of expected after surgery.&#xD;
&#xD;
          5. Diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PET &amp; Cyclotron Unit, Rigshospitalet,</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2009</study_first_posted>
  <last_update_submitted>March 20, 2009</last_update_submitted>
  <last_update_submitted_qc>March 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ulrik Lassen, MD., PH.D</name_title>
    <organization>Rigshospitalet</organization>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>PET/CT</keyword>
  <keyword>Surgery</keyword>
  <keyword>FDG</keyword>
  <keyword>staging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

